Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus letrozole versus letrozole alone for HR-positive/HER2-negative locally advanced breast cancer
ChiCTR1900024998Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in breast cancer comparing palbociclib + letrozole group with letrozole alone group (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900024998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024998.